Associations between Social Determinants of Health (SDOH) and Second-Line Type 2 Diabetes Medication Prescribing Authors: Jonathan Luong, BA¹, Annie Schuster, PharmD, FAMCP², Christopher Powers, PharmD², Tara Esse, PharmD, MBA, BCACP², Lee Parks, MD² ¹University of Washington School of Pharmacy ²Cigna Healthcare

Background

- Type II diabetes (T2D) has been well documented as one of the most common chronic diseases in the United States. It has a notably high prevalence in the Medicare population, affecting an estimated 27.5% of beneficiaries in comparison to 11.3% in the general population.¹
- Recent T2D guidelines increasingly encourage use of second-line medications, including but not limited to sodium-glucose cotransporter-2 inhibitors (SGLT2i), glucagon-like peptide-1 receptor agonists (GLP-1 A), dipeptidyl peptidase 4 inhibitors (DPP-4i), and sulfonylureas (SU) especially in patients with comorbidities such as heart failure and obesity.² Use of these agents in comparison to insulin has demonstrated comparable glycemic control and A1c reduction while having potential benefits found in adherence and decreased risk for adverse events such as hypoglycemia.³
- Existing literature demonstrates that health disparities exist in healthcare today and are exacerbated by the social determinants of health (SDOH) resulting in a direct impact on clinical outcomes. Claims analyses have shown that racial and ethnic minority patients are less likely to receive guideline-directed medical therapy (GDMT) and that SDOH have an influence on clinical outcomes for persons with diabetes. ^{4,5}

Objectives

• Conduct a cross-sectional claims analysis to identify notable associations between demographical variables, healthcare utilization, and social determinants of health (SDOH) and the likelihood of filling a T2D second-line agent.

Methods

- A cross-sectional study design utilizing medical and pharmacy claims data from a large Medicare insurer was used.
- Medicare Advantage Prescription Drug Plan (MA-PD) members were included if continually enrolled within both the prior year (January 1st, 2021 – December 31st, 2021) and the study year (January 1st, 2022 – December 31st, 2022).
- Inclusion criteria included members with at least two paid claims for metformin in the study year and diagnosis of T2D within the study year and prior year.
- To assess SDOH of members, a proprietary index covering associated domains (economy, education, food access, health coverage, and language) at the census level was utilized, with a low score corresponding with low exposure to social conditions that could hinder optimal health, and a high score corresponding with high exposure.
- Exclusion criteria included diagnosis of end-stage renal disease (ESRD) or hospice care within the study year or prior year.
- Chi-Square tests were used to determine the differences in proportions for categorical variables between the customers that either filled or did not fill a second-line agent.
- The probability of having a second-line agent filled or not filled was assessed using a multivariable linear regression.
- Statistical significance was defined as p < 0.05.



Results

Table 1: Member Baseline Characteristics


Second Line Therapy 4,236 19.2 71-75 5,568 76+ 25.5 4,216 19.1 11,087 9.726 10.944 Dual Status No Medicai 4.394 Low Income Subsidy 12,756 57.9 33.4 9,275 42.1 Special Needs Plan Type C-SNP D-SNP 19.7 Non-SNP 17.059 78.3 15,906 72.2 Plan Type НМО 20.034 90.9 1,805 Prior Metformin Use 9.2 1,728 7.8 19.788 90.8 20.303 92.2 Insulin Use (Part D) 17,452 79.2 89.8 2.232 4.579 Chronic Kidney Disease 75.8 15,969 72.5 5.277 24.2 6,062 27.5 Heart Failur 19,396 88.0 10.4 2,635 12.0 Medical Out of Pocket <\$50 8,408 38.2 \$50-\$199 18.1 \$200-\$599 4,612 20.9 >=\$600 4,675 21.5 5,035 22.9 Medical Total Cos 7,454 33.8 <\$1000 37.5 8,176 21.9 4,872 22.1 \$1000-\$2499 21.8 \$2500-\$7499 4,740 5,183 23.5 18.8 >=\$7500 4,094 4,522 20.5

Table 2: Member SDI Characteristics

	_			
	Second Li		ne Therapy	
	No		Yes	
	n	%	n	%
Social Determinants of Health Index (SD				
Low	3,221	14.8	3,131	14.2
Medium	5,175	23.8	5,252	23.8
High	5,239	24.1	5,167	23.5
Very High	8,152	37.4	8,481	38.5
SDI: Econo	my			
Low	3,002	13.8	2,875	13.1
Medium	3,977	18.3	3,986	18.1
High	5,839	26.8	5,945	27.0
Very High	8,969	41.2	9,225	41.9
SDI: Education				
Low	3,052	14.0	2,841	12.9
Medium	4,580	21.0	4,473	20.3
High	6,436	29.5	6,464	29.3
Very High	7,719	35.4	8,253	37.5
SDI: Food	Access			
Low	5,128	23.5	5,144	23.4
Medium	5,509	25.3	5,715	25.9
High	4,624	21.2	4,673	21.2
Very High	6,526	30.0	6,499	29.5
SDI: Language				
Low	9,275	42.6	8,888	40.3
Medium	3,318	15.2	3,224	14.6
High	3,574	16.4	3,538	16.1
Very High	5,620	25.8	6,381	29.0
SDI: Infras	tructure	!		
Low	4,346	20.0	4,344	19.7
Medium	6,209	28.5	6,417	29.1
High	4,377	20.1	4,448	20.2
Very High	6,855	31.5	6,822	31.0
SDI: Health Coverage				
Low	3,449	15.8	3,261	14.8
Medium	3,751	17.2	3,733	16.9
High	6,158	28.3	6,066	27.5
Very High	8,429	38.7	8,971	40.7

In total, 43,818 members met the study criteria and were included in the analysis.

- Statistically significant differences existed between most demographic characteristics in both the unadjusted and multivariate analysis, such as special needs plans (SNP) enrolled members, and low income subsidy (LIS) status. In the multivariate analysis, chronic condition SNP (C-SNP) and dual eligible SNP (D-SNP) members were 33.1% and 9.2% more likely to fill a second-line agent compared to non-SNP members respectively, and LIS members were 27.4% more likely to fill a second-line agent compared to non-LIS members.
- In the multivariate analysis, a few statistically significant associations were found between the levels of the SDOH domain index scores. Members with a very high economy score were 8.5% less likely to fill a secondline agent than those with a low score, members with a medium food access score were 11.4% more likely to fill a second-line agent than those with a low score, and members with a very high language score were 16.8% more likely to fill a second-line medication than those with a low score.
- In the unadjusted analysis, both increased member medical cost share and total medical cost were associated with a greater likelihood of filling a second-line agent; however in the multivariate analysis this association was only significant for total medical cost. A member total medical cost of \$1000-\$2499 was associated with a 16.3% increased likelihood to fill compared to a member total medical cost of <\$1000.
- Members with chronic kidney disease (CKD) were 23.4% more likely to fill a second-line medication, and members with Part D insulin use were 206.2% more likely to fill a second line agent.



Conclusions and Implications

- healthcare resource utilization, and SDOH domains

Limitations

- analysis.
- prescriber decision making and were not accounted for.

- to a different population.

References

- 2023. *Diabetes Care*. 2023;46(Suppl 1):S140-S157. doi:10.2337/dc23-S009
- Published 2021 Jul 1. doi:10.1001/jamanetworkopen.2021.14234

Additional Acknowledgements

- Kerry Christie, Cigna Medicare Business Analytics

• This analysis leveraged a large payer dataset to identify notable associations between demographics,

• Members enrolled in LIS, as well as SNP programs, were more likely to fill a second-line agent, suggesting that such programs may increase utilization through reduction of out of pocket spend or clinical programs that more effectively identify patients that may be eligible for second-line agents.

• Members with greater overall medical spend were less likely to be prescribed a second-line agent, most likely due to higher clinical risk associated with the patient population.

• In assessing SDOH and its association with prescribing likelihood, members with medium food access scores and high economic scores were less likely to be prescribed a second-line agent, suggesting that these populations may not be benefiting from resources or outreach available to those with lower scores, thereby making them less likely to fill or afford a 2nd line agent.

• Though customers with a CKD diagnosis were more likely to fill a second-line agent, a statistically significant difference was not detected for heart failure patients, which may indicate that clinical programs are warranted to educate on heart failure- related benefits and to recommend use where appropriate.

• Race and ethnicity were not captured as a domain of SDOH and therefore not accounted for in the

Clinical factors such as adverse effects, A1c level, and patient adherence that would have contributed to

• Information regarding fill patterns on prescriber level was not included in the analysis.

• The SDOH index utilized in the analysis incorporated data from a census level and was therefore generalized to all members in that geographic area, decreasing its accuracy on a member specific level.

• This study was conducted using members from a single payer, which may limit its ability to be generalized

1. Diabetes disparities in Medicare - Centers for Medicare & Medicaid Services. Diabetes Disparities in Medicare Fee-For-Service Beneficiaries. https://www.cms.gov/AboutCMS/Agency-Information/OMH/Downloads/Data-Snapshots-Diabetes.pdf. 2. ElSayed NA, Aleppo G, Aroda VR, et al. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-

. Tsapas A, Avgerinos I, Karagiannis T, et al. Comparative Effectiveness of Glucose-Lowering Drugs for Type 2 Diabetes: A Systematic Review and Network Meta-analysis. Ann Intern Med. 2020;173(4):278-286. doi:10.7326/M20-0864 Essien UR, Kim N, Hausmann LRM, et al. Disparities in Anticoagulant Therapy Initiation for Incident Atrial Fibrillation by

Race/Ethnicity Among Patients in the Veterans Health Administration System. JAMA Netw Open. 2021;4(7):e2114234.

5. Walker RJ, Smalls BL, Campbell JA, Strom Williams JL, Egede LE. Impact of social determinants of health on outcomes for type 2 diabetes: a systematic review. *Endocrine*. 2014;47(1):29-48. doi:10.1007/s12020-014-0195-0

Thank you to Pfizer Inc. for funding the AMCP Foundation Managed Care Summer Internship Program. Poster presented at AMCP Nexus 2023, October 16-19, Orlando, FL



